SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Attention is centered on Metas quarterly earnings and AI spending outlook, particularly whether Muse adoption and rising data-center capex can translate into growth and returns. Traders are split between optimism for strong results and AI demand and concern about costs, margins, possible share issuance, and the reported New Mexico privacy penalty.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas earnings and speculation about a potential SpaceX merger are driving attention, with traders weighing the AI-and-robotics growth story against concerns about the auto business, valuation and deal terms. The companies committees are exploring a combination, not confirming one, leaving bullish merger hopes at odds with expectations of an earnings-related pullback.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBMs quarterly results beat revenue and earnings expectations, and the company raised its full-year free-cash-flow outlook, prompting a positive share reaction. Traders welcomed the stronger cash-flow guidance but debated weak mainframe sales, softer consulting, and narrower-than-expected margins.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Researchs quarterly earnings and forward guidance are the dominant focus, with traders reacting to claims that results exceeded expectations. Optimism about the report and the semiconductor-equipment outlook is tempered by pre-earnings selling and speculation about a leak, which remains unconfirmed.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Concern over slowing sales in Celsiuss core brand and mixed Nielsen data is weighing on sentiment, with traders watching whether Alani Nus growth and upcoming earnings can offset the weakness. Bulls see value in the pullback and cite Alanis momentum and insider buying, while bears point to competition, margin pressure, and management execution; Pepsi buyout talk remains speculation.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp

Reports that the Navy has halted further purchases of BlackSeas GARC drone boats are driving a sharp selloff, with traders concerned about the programs importance to AEVEX after the BlackSea acquisition. Some view the reaction as excessive, arguing the issue is limited to one program and that other defense opportunities remain.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Traders are focused on the full Phase 3 INTerpath-001 melanoma cancer-vaccine data from Moderna and Merck at ESMO, following previously reported positive trial endpoints. The sharp rally has fueled bullish hopes for Modernas oncology platform and short-squeeze talk, while skeptics argue expectations and valuation are stretched and warn of a possible sell-the-news pullback.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq and tech-stock selloff, fueled by hotter inflation concerns and pressure on AI and semiconductor shares, is weighing on TQQQ, which magnifies moves in the Nasdaq-100. Traders are split between buying the dip in hopes of an oversold bounce and warning that bearish momentum and rate concerns could drive further declines.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is in focus ahead of its Q3 report, with traders weighing whether AI and data-center power demand can support further growth and guidance. Bullish investors point to recent power deals and the broader AI-energy theme, while others cite the stocks premium valuation, macro pressure and risk of a sell-the-news reaction.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

Discussion centers on broad-market risk, with traders warning that elevated valuations, heavy AI investment, inflation, oil prices, and rising bond yields could pressure U.S. stocks. Others favor VTI as a diversified, low-cost long-term holding and advocate continued buying and compounding despite volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAmgen is demonstrating strong top-line growth driven by a diverse portfolio in oncology and rare diseases...

AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026

AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026PR NewswireTHOUSAND OAKS, Calif., Oct. 20, 2026 THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen(NASDAQ:AMGN)will host a webcast call for...

AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.read more...

TEZSPIRE DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS

TEZSPIRE DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS TEZSPIRE DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITISPR NewswireTHOUSAND OAKS, Calif., Oct. 20, 2026 Symptom Improvements Versus Placebo at Week 24 Were Sustained...

Here's Why Amgen (AMGN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of $230.37 billion.read more...

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Bet on These Healthcare ETFs to Benefit From the Aging US Population

With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>No U.S. Food and Drug Administration-approved medicine currently treats persistent systemic Sjögren’s disease.&nbsp;</li><li>Amgen’s second late-stage study in patients with Sjögren’s disease is expected to finish in the fourth quarter.&nbsp;</li><li>Citi argues that the magnitude of efficacy and competitive profile of dazodalibep “remain open questions” until more “fulsome data” are presented.</li></ul><p>Shares of Amgen (AMGN) rallied as much as 5% on Tuesday after the company said its experimental autoimmune drug dazodalibep reduced disease intensity in patients with moderate-to-severe systemic Sjögren’s disease in a late-stage study.</p><p>At the time of writing, AMGN was trading 4% higher as investors reacted to Amgen’s first late-stage win for a potential systemic treatment in a disease that still has no approved disease-modifying therapy. However, Citi is awaiting more details on the study.</p><h2 class="st-heading-2">Positive Trial Results</h2><p>The OASIZ 301 trial enrolled about 621 adults with meaningful whole-body disease activity. After 48 weeks, dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems. The company said gains appeared as early as week 4 and lasted through the study.</p><p>Sjögren’s is a common autoimmune illness that attacks moisture-producing glands and can spread to joints, nerves and major organs. Patients often live with dry eyes and mouth, severe fatigue and chronic pain. No U.S. Food and Drug Administration-approved medicine currently treats persistent systemic disease.</p><p>Side effects were generally mild to moderate in the trial, Amgen said. The most common events seen more often with the drug than placebo included colds, urinary tract infections, higher blood pressure and infusion reactions. Few patients stopped treatment, and rates were similar across groups. No imbalance in blood clots or opportunistic infections was observed.</p><p>Amgen gained dazodalibep through its 2023 purchase of Horizon Therapeutics. A second late-stage study in patients with heavy symptoms but lower systemic activity is expected to finish in the fourth quarter.</p><h2 class="st-heading-2">Citi Still Wants The Full Picture</h2><p>Citi said Amgen’s dazodalibep delivered “positive” late-stage results in systemic Sjögren’s, which reduces clinical risk for “a potentially underappreciated I&amp;I (Immunology and Inflammation) asset.” However, several details that matter are absent from the topline release, so the firm argues that the magnitude of efficacy and competitive profile “remain open questions” until more “fulsome data” are presented. Citi has a Neutral rating and a $405 price target on Amgen shares, implying a potential upside of 3% from the stock’s Monday close.</p><p>Other firms developing Sjögren’s treatments include Novartis and Johnson &amp; Johnson.</p><h2 class="st-heading-2">How Did AMGN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AMGN stock stayed in ‘bearish’ territory over the past 24 hours, while message volume remained ‘low.’</p><p><a href="https://stocktwits.com/symbol/AMGN">AMGN stock</a> has gained 25% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/twin-moves-vrtx-rises-on-kidney-disease-trial-results-maze-rallies-harder/cZMPusmRB7c">Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)

In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.

Vanguard S&P 500 ETF

Track AMGN stock price, charts, news and real-time market activity on Stocktwits. Join the AMGN message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around AMGEN Inc stock.

AMGN Stock Price Today - AMGEN Inc. News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$438.34
Prev Close	$438.94
Open	$440.21
Dividend Yield	2.91%
50-Day Moving Average	$415.73
Beta	0.52
Avg. Volume	3.19M
PE Ratio	27.27

52-Week High	$447.03
52-Week Low	$288.00
Market Capitalization	$237.31B
EPS (Annual)	$14.23
Price to Book	20.30
Revenue Per Employee	$1.17M

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

AMGN Fundamentals